This is a really important topic because so many times when people develop a new problem with their HS, some practitioners or offices are quick to refer them out. A good example is an abscess. One of these cysts turns into an abscess, it’s actively draining. I believe most people are comfortable with doing an incision and drainage. But many times people and clinicians are underutilizing intralesional injections. This is a quick procedure that can provide a lot of relief and less scarring for the patient. Obviously, there are limitations to that. But for some of the bigger areas that are more involved and resistant to I&Ding [incision and drainage] or intralesional injections, doing a deroofing procedure can provide a lot of benefit for patients. This is a way to keep the patient in your practice, have good continuity of care, and treat them effectively without referring them to a general surgeon. There are lots of resources available for that procedure, but that is something that I encourage everyone to get better at doing because it really provides a lot of relief for those patients with HS.

Ask your patients about HS. There is definitely a knowledge gap for practitioners across all specialties. And many times patients are not forthcoming with having this disease. And so when you’re seeing someone who comes in for acne, or you’re seeing someone who comes in and you’re draining an abscess, have the conversation and ask them, “Do you have these anywhere else? How many cysts have you had in your life?” Oftentimes, that opens up a good conversation, and patients will be more forthcoming with having this disease. Also, for the patients who have HS, talk to them about the benefit of early treatment. We’ve discussed this here, but a lot of people feel that biologic treatment is only necessary when they have severe disease or stage III Hurley disease, and that is not the case. Early intervention in this window of opportunity can provide people with an improved quality of life, less surgery, less sequelae from this disease, so that is really important. And also, develop a good multidisciplinary team. People in the medical community—some have very strong personalities. And it may take a little bit of time to find a group of individuals you trust to refer. Whether it’s a psychiatrist or a surgeon or whoever you’re working with for these patients, making sure that you’re on the same page about what it takes to truly treat this disease effectively is so important. And the last is to make sure you’re going to tell your patients that you’re going to follow them closely, you’re going to be seeing them frequently, you’re going to make sure that their medications are working for them. If they develop a hot spot or a draining abscess, make sure that you tell them that you’ll get them in quickly to manage this to prevent them from going to ERs [emergency rooms] and urgent care facilities. And just having polypharmacy, because so many times these patients are being bounced around. So just let them know that you care and that you’ll be there with them throughout this journey.

An expert in dermatological conditions discusses office-based procedures that can benefit patients with HS and shares clinical pearls for the management of the disorder.

Clinical Pearls for the Management of HS

Andrew Baker PA-C, MBA

How Pollen Food Allergy Syndrome Contributes to EoE, with Antonella Cianferoni, MD, PhD

Antonella Cianferoni, MD, PhD, from Children’s Hospital of Philadelphia, told 

 that ≥ 90% of cases of eosinophilic esophagitis (EoE) are linked to allergic rhinitis, often triggered by pollen

 As a result, patients with EoE face a high risk of developing pollen food allergy syndrome.

“If you have any eosinophilic esophagitis that is not controlled…foods that cause the pollen Food Allergy syndrome can cause an acute reaction in your esophagitis,” Cianferoni said.

Along with an itchy mouth and swollen lips, patients may experience reflux symptoms or a constriction in their chest. This chest restriction symptom appears to be more frequent in adults but rarer in children.

“What is not completely clear is if these food[s] related with the pollen syndrome can really cause the eosinophilic esophagitis [alone],” Cianferoni said.

Cianferoni presented “Pollen Food Allergy Syndrome (PFAS) in Immunoglobulin E (IgE) and Non-IgE Mediated Food Allergies” at the 

2025 American Academy of Allergy, Asthma, & Immunology (AAAAI)

 annual meeting in San Diego on Friday, February 28. Her presentation covered the 

molecular diagnosis of pollen food allergy syndrome

, the management of pollen food allergy syndrome in IgE-mediated food allergies, and the role of pollen food allergy syndrome in EoE. 

 sat down with Cianferoni at the meeting to discuss these subject matters.

Pollen food allergy syndrome cases have increased in the past 10 – 20 years. Although this is a mild form of food allergy, Cianferoni said the syndrome can sometimes, although rarely, lead to a more severe reaction. Patients may need to carry epinephrine and strictly avoid foods.

For the management of pollen food allergy syndrome, Cianferoni said the options are either avoiding or cooking vegetables or fruits. Pollen immunotherapy, either injectable or sublingual, could be another treatment option but needs further exploration.

Some studies have shown pollen immunotherapy could be effective for pollen food allergy syndrome, but some studies showed the opposite. Cianferoni said it is recommended to give a patient pollen immunotherapy only if it targets the allergic rhinitis. By treating the allergic rhinitis, it may, in the long run, treat the pollen-associated food allergy.

“But [with] pollen allergy in the respiratory tract, it's more debatable if doing immunotherapy with the pollen can really treat the pollen allergy syndrome,” Cianferoni said.

Nowak-Wegrzyn A and Cianferoni A. 1502 - Pollen Food Allergy Syndrome (PFAS) in Immunoglobulin E (IgE) and Non-IgE Mediated Food Allergies. Presented at AAAI 2025 in San Diego on February 28 at 11:30 am.

Derman, C. Pollen Food Allergy Syndrome vs Other Allergies, with Antonella Cianferoni, MD, PhD. HCPLive. March 10, 2025. 

https://www.hcplive.com/view/pollen-food-allergy-syndrome-vs-other-allergies-with-antonella-cianferoni-md-phd

Cianferoni discusses how pollen food allergy syndrome contributes to eosinophilic esophagitis (EoE) and potential management strategies.

Antonella Cianferoni, MD, PhD

Devrey Martin is a Master’s Student in Forensic Psychology at the University of Denver with interests in the overlap of forensic psychology with health psychology and neuropsychology. During her first year, Devrey has been involved in traumatic brain injury research and writing for an advocacy newsletter. She aims to provide forensic evaluations and assessments while advocating for prison reform.

Devrey Martin, BS

1:25- Rationale for high dose aflibercept

22:29- Faricimab and role of ang-2 inhibition

Ehsan Rahimy, MD; David G. Miller, MD, and Jordana Fein, MD, discusses how 8 milligram aflibercept and faricimab, newer anti-VEGF therapies for retinal diseases, offer improved durability with comparable safety profiles to existing treatments, allowing less frequent injections while maintaining equivalent vision outcomes.

Advancing Retinal Disease Treatment – The Next Generation of Anti-VEGF Therapies 

Ehsan Rahimy, MD

Eric Lawitz, MD, is the medical director of the Texas Liver Institute and a clinical professor of medicine at the University of Texas Health San Antonio.

Trivedi and Lawitz review long-term data from the phase 3 open-label ASSURE study and explain what they add to our understanding of seladelpar for PBC.

Insights from Long-Term ASSURE Data for Seladelpar

 treatment landscape has long been limited to just a handful of agents with limited efficacy, 2024 saw a major shift in PBC management with the addition of 2 new second-line therapies.

Seladelpar (Livdelzi), a proliferator-activated receptor (PPAR) delta agonist, was one of these recent additions to the PBC treatment armamentarium and was a major topic of discussion at 

The Liver Meeting 2024 from the American Association for the Study of Liver Diseases (AASLD)

Findings from a 2.5-year interim analysis of the ongoing open-label phase 3 ASSURE study were presented in a late-breaking abstract at the meeting and highlight seladelpar’s sustained efficacy and long-term safety for the treatment of PBC.

In this segment, which is the final installment of a 4-part series, experts Palak Trivedi, MD, PhD, and Eric Lawitz, MD, discuss the long-term ASSURE data and what they add to our understanding of seladelpar’s safety and efficacy for PBC.

Trivedi begins by emphasizing the significance of seladelpar’s long-term safety profile, calling attention to the lack of new treatment-emergent adverse events or concerning safety signals. While acknowledging the inherent limitations of safety extension studies without matched control groups, he describes how the ASSURE data provide confidence in the drug’s sustained biochemical response and tolerability, additionally advocating for real-world studies to validate these findings and establish whether seladelpar improves transplant-free survival over time beyond its biochemical markers.

Similar to Trivedi, Lawitz highlights the importance of long-term follow-up in chronic therapies. He notes that the ASSURE data not only confirm the stability of seladelpar’s safety profile but also reveal a potential increase in efficacy with extended treatment. He notes the consistent durability and lack of unexpected toxicities offer clinicians greater confidence in prescribing seladelpar for prolonged use.

: associate professor and honorary consultant hepatologist and clinical research director for industry engagement at the University of Birmingham

: medical director of the Texas Liver Institute and a clinical professor of medicine at the University of Texas Health San Antonio

Relevant disclosures for Trivedi include Bristol Myers Squibb, Gilead, Intercept, CymbaBay, and others. Relevant disclosures for Lawitz include 89Bio, Boehringer Ingelheim, Merck, Novo Nordisk, Sagimet Biosciences, AstraZeneca, Bristol Myers-Squibb, Cymabay, Eli Lilly, Gilead Sciences, GlaxoSmithKline, Intercept, Ipsen, Madrigal, Novartis, Regeneron, Takeda, Terns, Viking Therapeutics, AbbVie, and others.

Brooks A. FDA Grants Accelerated Approval to Seladelpar (Livdelzi) for Primary Biliary Cholangitis. HCPLive. August 14, 2024. Accessed December 4, 2024. 

https://www.hcplive.com/view/fda-grants-accelerated-approval-to-seladelpar-livdelzi-for-primary-biliary-cholangitis

Brooks A. Seladelpar (Livdelzi) Demonstrates Long-Term Benefit for Primary Biliary Cholangitis. HCpLive. November 15, 2024. Accessed December 4, 2024. 

https://www.hcplive.com/view/seladelpar-livdelzi-demonstrates-long-term-benefit-primary-biliary-cholangitis

The treatment landscape for primary biliary cholangitis (PBC) has evolved with the introduction of new second-line therapies, including seladelpar, a PPAR delta agonist. At The Liver Meeting 2024, findings from the ASSURE study highlighted seladelpar's sustained efficacy and long-term safety. Experts Palak Trivedi and Eric Lawitz emphasized the drug's stable safety profile and potential increased efficacy over time. They advocated for real-world studies to further validate these findings and assess seladelpar's impact on transplant-free survival beyond biochemical markers.

Eric Lawitz, MD

John Salgo, MD

The last piece is about education. This is important because to make a good shared decision-making process with the patient, they have to be on the same page. There’s a huge amount of education that has to happen. Of course, we all have luxurious amounts of time. You guys usually have, what, 1 to 2 hours for a new visit? Maybe longer—it’s only a few patients a day. No. We’re crunched. You have crunched time, and you have so much to cover. Sometimes the visit has many factors: where have you been? What are you using currently? What are your hopes, your fears, concerns? Then you get derailed. All they want to talk about is food. What food should we avoid? If we mention that, it can derail the whole visit. You’re trying to get to the next step to figure out how to get their skin better, and they’re doing this.

That doesn’t take into account the paperwork that has to happen after: the insurance forms, the prior authorization, the patient support stuff—all these things. How do we do that? One thing that’s so important is to bring external resources. I’m obsessed with handouts. I’m the king of handouts. Every time I see anybody for anything, they’re going home with a handout, and it’s usually going to list my action plan: what to do when you’re flaring up and what to do when you’re better. That’s such a big deal for me because it’s cut a lot of calls. Not 100%, but many calls [are answering the questions], “Which do I do first? Do I put this 1 on and then this 1?” I put them in numeric order. “In the morning, you’re going to do 1, 2, and 3.” We can really bring them through that.

The other piece that’s important is utilizing some of the national organizations that have patient support resources. I’m very conflicted because I’m a board member of the National Eczema Association. I don’t get paid any money. In fact, I donate a lot every year. I love the National Eczema Association. They’re a nonprofit organization that does a lot of patient advocacy support and education. I try to have my patients go to their website , to get signed up, to learn a little more about it. It’s nice when it doesn’t have to come directly from us. Sometimes they have a rapport with us, they understand us, but it’s nice to hear someone else’s voice, to get another opinion. That can help and give them some of the tools that can help them ask the good questions at the next visit, because I don’t like to be pushy. 

On the first visit, sometimes I say, “Here are some options. I want you to think about this. Here’s some homework for you to read. Let’s talk, either by phone”—if they’re from out of state or from far away—“or when I see you in a few weeks, we’ll make our decisions at that point.” How do you guys feel about the education burden that we have?

I agree. All of our patients are—if they haven’t already before they come to the visit—going to Google and Facebook to crowdsource and ask for advice from trusted friends and family members beyond their trusted allergist or dermatologist. Beyond the sheet that has all those important, point-by-point instructions, there needs to be a trusted links list. Something like the [National] Eczema Association and our national societies, which have great patient handouts. Let them kind of go down the rabbit hole online in a safe place, in a place they’re going to get good information.

Giving links and trusted sources are really helpful. But I also find that having that patient back with a short turnaround time is important. We’re all busy, but in patients with atopic dermatitis, we give them homework, we give them food for thought, but they need to come back shortly thereafter with questions fresh in mind. [Once they’re] able to move the ball along the field, get closer to that touchdown, get closer to that goal line, we can make management decisions incrementally. It’s OK to make management decisions incrementally for these patients. If you do that, they’ll follow you along that pathway.

I was going to make 1 quick [point]. We’ve alluded to the food thing. There may be some listeners [wondering], “Why are they laughing about the food? Why aren’t they talking about that?” I can speak a little for Dr Jain because I just attended 1 of his amazing lectures about food allergy and atopic dermatitis. The point—and the way I say it to my patients—is that I wish the food were the cause. When food is the cause, it’s easy. Arguably, you don’t actually have atopic dermatitis. You have an eczematous food reaction—you’re done, you don’t need us, you don’t need any of this. But for many patients, food may be playing some role. It might be inflammatory. They may have some food triggers. Of course, there’s a huge concurrence of real food allergies that are IgE mediated.

It’s a complex, messy thing, but it’s often not where the money is to get the skin better. There’s this tension because the patients want to focus on the diet, “How can I fix my diet to get better?” [We say], “I don’t know.” Even if you did a super-severe, extreme diet—we’ve all had patients with literal malnutrition because they’ve been so stringent on their diet, and their eczema is still terrible. It’s trying to redirect, not because we’re trying to push drugs on somebody, but because we’re trying to help them. Some of the patients and families have done this for years. I’ll just sit there and say, “You would’ve found it without me. You’ve cut everything out. You’re feeding the child rocks and water, but his eczema is still bad. I don’t think it’s food. I want it to be too, but can we work on other things?”

One of the little tools in my toolbox that I’ll share—this is a pretty universal thing; we all feel the pain of this is that I often say to families who are fixated on it, “When the skin is super inflamed, like now, when it’s a mess, it’s similar to when you get up on the wrong side of the bed.” You’re in a bad mood. No matter what anybody says to you, you’re going, “Grr.” Somebody says, “Good morning,” and you’re, “Grr.” But when you get up and you’re in a good mood, even if someone says, “You’re a jerk,” you say, “Have a great day.” It rolls off you.

It’s very difficult to evaluate what’s triggering your skin when it’s a mess, so I say, “Let’s get it better.” Let’s spend a little time cleaning things up. If there are still triggers, we can then see with much clearer eyes If they had an aha moment when they ate—fill in the blanks—dairy, gluten, strawberries, whatever it may be. That definitely made it worse. But right now, we can’t even see that. I put that there not because we don’t take it seriously. We do, but it could take up all the time. Sometimes that’s all people want to talk about. We have to redirect, because I want to get people better. Do you guys agree with that? Not to derail it too much, but it’s so important.

Absolutely. When we talk about what works and what helps patients get buy-in, we take for granted that we understand this pathology of atopic dermatitis, but they don’t. You just spoke about this with regard to their focus on foods or other things, what mindset they come in with. We need to take a step back and teach them that this is a disease where there’s barrier dysfunction, helping them understand that we’re learning that this is true not only of atopic dermatitis but also other type 2 inflammatory diseases, whether it’s asthma, allergic rhinitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis.

We know that there are these similarities with this barrier dysfunction, and that barrier dysfunction leads to this inflammation. That’s how you develop food allergies. It happens first there. We need to help them understand this so that they get the focus away from some things that they have preconceptions about, and then we can educate them about the options to manage that and help restore that function to help their skin better. That’s hugely helpful. When this comes from reputable sources like the National Eczema Association, the AAD [American Academy of Dermatology], our societies in allergy, getting that same message repeatedly helps.

We did some survey on patients’ perceptions about bathing. You hear these patients coming in, saying that they’ve been told 15 things about what they should do with bathing, and they’re just confused. So to have some science to back this up gives us credibility, and that allows for the buy-in that ultimately leads to success in skin improvement.

Educating patients about their disease course is very important at the outset. It’s important to set expectations, and there’s no more important way for me to do that than to tell them this is not something you’re doing. It’s not your fault. It’s a genetic skin condition, and it’s a condition that waxes and wanes over time. There are going to be periods when you forget that you have eczema. There are going to be periods when it’s very flared. Our job is to control those flares so that you’re not having flares very often and when you do have flares, to not be concerned about treating them at the first sign of trouble.

One way to do that is to talk about the use of steroids and how to properly use them so that they’re not afraid to use them. Another way is to use nonsteroidal medications that might promote less fear within the patient or the parents so that they use them at the first sign of trouble. I always say that it’s like a little fire that’s burning. The sooner you put it out, the better off you’ll be—but you have to completely put it out. If you use your medication for a few days and then there are still some embers there, it will come right back. It’s important to set those expectations.

A third thing that’s very important to talk about is avoiding systemic steroids. Very commonly, patients come to the office with chronic waxing-and-waning flares. It’s a vicious cycle, and it’s usually triggered by the use of systemic steroids, either injectable or oral prednisone or Medrol dose packs. What happens is the patient’s skin rebounds once they come off their systemic steroids. It’s important to educate parents, patients, and providers that using systemic steroids should be a bridge to some other therapy and should not in and of itself be the plan to treat someone’s atopic dermatitis. In the long term, they have adverse effects. In the short term, they’re going to create a rebound that’s only going to continue their waxing-and-waning flare cycle.

Shared insight on the best ways to educate patients on their atopic dermatitis and explain the nuances of available therapies.

Educating Patients on Atopic Dermatitis and Inflammation 

Marc Serota, MD

Mercedes E. Gonzalez, MD, is a clinical assistant professor at the FIU Herbert Wertheim School of Medicine and the Phillip Frost Department of Dermatology at the Miller School of Medicine.

 that the US Food and Drug Administration (FDA) had accepted their supplemental New Drug Application (sNDA) for roflumilast cream 0.05% (Zoryve) as a topical for children with mild to moderate 

 team spoke with a clinical trial investigator for the INTEGUMENT-PED study.

Mercedes E. Gonzalez, MD, is a clinical assistant professor at the FIU Herbert Wertheim School of Medicine and the Phillip Frost Department of Dermatology at the Miller School of Medicine. Gonzalez spoke with the 

 team about roflumilast’s recent data and its use as a once-daily topical phosphodiesterase-4 (PDE4) inhibitor in children aged 2 - 5 years.

Findings on Roflumilast Cream 0.5% for Children with Atopic Dermatitis, with Mercedes Gonzalez, MD

“This was a pediatric atopic dermatitis that included patients 2 years to 5 years of age who had mild to moderate atopic dermatitis and had to have at least 3% body surface area to be enrolled in the trial,” Gonzalez said. “This was a 4-week trial. It was a randomized, placebo-controlled trial. Patients were randomized 2 to 1 to receive roflumilast 0.05% cream versus a vehicle, and they were followed for 4 weeks. The primary efficacy endpoint was IGA improvement. So this was an improvement in IGA score of 0 or 1, as well as an EASI 75 at 4 weeks.”

The findings highlighted by Gonzalez represented the conclusion of the INTEGUMENT-PED study, during which the research team followed up the INTEGUMENT-1 and INTEGUMENT-2 phase 3 analyses.

 437 subjects were included in the trial who were given roflumilast cream and 215 were in the vehicle arm.

Gonzalez’s team highlighte that at the 4-week mark, there was a significantly higher proportion of individuals included in the roflumilast cream cohort who had visibly attained an EASI-75 (39.4% versus 20.6%; 

 < .0001), as well as Validated Investigator Global Assessment for atopic dermatitis (vIGA-AD) Success (25.4% versus 10.7%; 

 < .0001) and Worst Itch-Numeric Rating Score (WI-NRS) Success (35.3% versus 18.0%; nominal 

“Because of the data, I'm able to say that there's a significant chance that itch is going to improve quickly and that the skin lesions are going to go away pretty quickly within that 4-week time frame,” Gonzalez explained. “In addition, it does not have the side effects associated with the traditional topical corticosteroids. The rates of adverse events in the trial were extremely low, with less than 1% reporting stinging and burning from this medication. So that's important.”

It has been noted previously that the FDA has a PDUFA target action date set for October 13, 2025 for the roflumilast cream 0.05% application.

 For more information on this subject, view the full interview video posted above.

The quotes contained in this interview summary were edited for clarity.

Arcutis Biotherapeutics. U.S. FDA accepts Supplemental New Drug Application For Arcutis’ ZORYVE® (roflumilast) cream 0.05% for the treatment of children aged 2 to 5 with mild to moderate atopic dermatitis. Arcutis Biotherapeutics. February 26, 2025. Accessed February 26, 2025. 

https://www.arcutis.com/u-s-fda-accepts-supplemental-new-drug-application-for-arcutis-zoryve-roflumilast-cream-0-05-for-the-treatment-of-children-aged-2-to-5-with-mild-to-moderate-atopic-dermatitis/

Eichenfield, L.F., Serrao, R., Berk, D.R., et al (2025). Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2–5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled Trial. Pediatric Dermatology. 

This interview highlights recent findings on roflumilast cream 0.05% for patients aged 2 to 5 years with mild to moderate atopic dermatitis.

Findings on Roflumilast Cream 0.05% for Children with Atopic Dermatitis, with Mercedes Gonzalez, MD

Mercedes Gonzalez, MD

Reynold Panettieri, Jr, MD, Robert Wood Johnson Medical School 

 – In what has been a transformative year for ulcerative colitis (UC) treatment, the IL-23 class has solidified its role as a key therapeutic treatment option. With Johnson & Johnson’s Tremfya now joining AbbVie’s Skyrizi and Lilly’s Omvoh, gastroenterologists have three powerful IL-23 options at their disposal.

The IL-23 class has rapidly gained significant momentum, capturing one-tenth of the advanced systemic UC market over the course of 2024, according to Spherix’s 

 service. This rapid growth is fueled by the strong reputation of IL-23 inhibitors, reinforced by Skyrizi’s success and Tremfya’s recent approval, positioning IL-23s as the leading mechanism of action for UC in the eyes of physicians (n=106)—a trend Spherix has closely monitored over the past two years.

The study also shows that Tremfya has made a strong debut, with a large majority of gastroenterologists aware of its September 11

 approval in UC. Over one-fifth of gastroenterologists have already prescribed Tremfya, surpassing early trial rates for Lilly’s Omvoh at a similar post-launch timeframe, but falling short of what was tracked for Skyrizi. In the coming six months, gastroenterologists project Tremfya’s growth to outpace Omvoh, positioning it as the likely second most-prescribed IL-23 therapy.

Differentiation among the IL-23 therapies will be essential as Tremfya and Omvoh vie for position against Skyrizi, the current frontrunner. Already, a majority of gastroenterologists view the IL-23 agents as clinically distinct, with Skyrizi emerging as the preferred option. AbbVie, Johnson & Johnson and Lilly are making efforts to differentiate their agents. Omvoh, for instance, stands out for its impact on bowel urgency—a symptom highlighted by Lilly’s CONFIDE study. Tremfya is noted for its dual mechanism that binds not only to IL-23 but also to CD64, a receptor on IL-23-producing cells. Skyrizi distinguishes itself with an on-body injector device and its earlier approval for Crohn’s disease, which gave physicians valuable experience with the drug before its approval for UC.

As 2024 closes, Spherix anticipates an equally dynamic 2025 as IL-23s continue to shape the competitive landscape in UC. Spherix’s gastroenterology team will continue to monitor UC market developments through its 

 service in addition to tracking each specific launch closely in its 

 is an independent service providing strategic guidance through quarterly or semiannual reports, which include market trending and a fresh infusion of event-driven and variable content with each wave. The reports provide an unbiased view of the competitive landscape within rapidly evolving specialty markets, fueled by robust HCP primary research and our in-house team of experts.

 is an independent service providing monthly benchmarking of newly launched products for the first eighteen months of commercial availability, augmented by a quarterly deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand.

Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle.

The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community.

As a trusted advisor and industry thought leader, Spherix’s unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth.

To learn more about Spherix Global Insights, visit 

For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here: 

https://clientportal.spherixglobalinsights.com

Jim Hickey, Gastroenterology Franchise Head

: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight’s analysis and do not imply a relationship with or endorse.

The IL-23 class has emerged as a pivotal treatment option for ulcerative colitis (UC), with Johnson & Johnson's Tremfya joining AbbVie's Skyrizi and Lilly's Omvoh. This class has captured a significant market share, driven by the success of Skyrizi and Tremfya's recent approval. Differentiation among these therapies is crucial, with Skyrizi leading due to its unique features. Spherix Global Insights anticipates continued growth and competition in the UC market, providing strategic guidance through its RealTime Dynamix™ and Launch Dynamix™ services to monitor these developments.

Future intensified intra-class competition among Omvoh, Skyrizi and Tremfya is expected as each brand attempts differentiation.

Authors